https://www.daytrader.dk/genmab-sydbank-anbefaling-haeves-til-koeb-efter-kaempeopkoeb/
Genmab/Sydbank: Anbefaling hæves til "køb" efter kæmpeopkøb - Daytrader.dk
Sep 29, 2025 - Genmab/Sydbank: Anbefaling hæves til "køb" efter kæmpeopkøb
genmabsydbankanbefalingtilefter
https://www.inderes.se/releases/notice-to-convene-an-extraordinary-general-meeting-of-genmab-as
Notice to Convene an Extraordinary General Meeting of Genmab A/S - Inderes
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S...
extraordinary general meetingnoticeconvenegenmabinderes
https://www.oanda.com/eu-cz/trading/shares/us/genmab-a-s
Genmab A/S (GMAB) Trading | Shares / Shares CFDs | OANDA
Trade Genmab A/S (GMAB) shares CFDs with OANDA. View live charts and current market interest for this stock.
a sgenmabgmabtradingshares
https://aktieakademi.dk/tag/genmab-teknisk-analyse/
Genmab teknisk analyse - Aktieakademi
genmabtekniskanalyse
https://www.onvista.de/derivate/Faktor-Optionsscheine/handelsplaetze/292895986-PL9TX5-DE000PL9TX50
Alle Börsenkurse PL9TX5 • DE000PL9TX50 | Faktor-Optionsschein auf GENMAB • onvista
Schnell zur Übersicht aller aktuellen Börsenkurse für den Handel. Alle Kurse zu Faktor-Optionsschein auf GENMAB (PL9TX5 • DE000PL9TX50).
allefaktoraufgenmab
https://fedthjem.dk/genmab-nyheder/
Genmab nyheder
genmabnyheder
https://www.genmab.com/privacy/clinical-trials-privacy-notice-gct3013-03
Welcome to Genmab
welcome togenmab
https://www.us.genmab.com/safety-reporting
Welcome to Genmab
welcome togenmab
https://www.biocentury.com/article/37201/genmab-to-reduce-headcount
BioCentury - Genmab to reduce headcount
Genmab A/S (CSE:GEN) plans to reduce headcount by about 300 (57%) to about 230 and sell its manufacturing facility in Brooklyn Park, Minnesota. Genmab said...
genmabreduceheadcount
https://www.daytrader.dk/genmab-sikrede-sig-merus-for-naesen-af-andre-interesserede/
Genmab sikrede sig Merus for næsen af andre interesserede - Daytrader.dk
Oct 22, 2025 - Genmab sikrede sig Merus for næsen af andre interesserede
genmabsikredesigmerusandre
https://pj.jiho.jp/article/250573
Genmab Files Epkinly for Follicular Lymphoma Grade 1-3A in Japan | PHARMA JAPAN
Genmab said on March 11 that it has filed its IgG1 bispecific antibody Epkinly (epcoritamab), being …
follicular lymphomain japangenmabfilesepkinly
https://www.fiercebiotech.com/biotech/genmab-pays-8b-buy-merus-and-phase-3-stage-bispecific-wowed-analysts?
Genmab pays $8B to buy Merus and phase 3-stage bispecific
Sep 29, 2025 - Genmab is continuing to build its pipeline of wholly owned cancer assets, this time paying $8 billion for Merus and its bispecific antibody.
to buygenmabpaysmerusphase
https://www.themuse.com/jobs/genmab/regional-business-director-west-solid-tumor-ec5104
Regional Business Director -West Solid Tumor at Genmab | The Muse | The Muse
Find our Regional Business Director -West Solid Tumor job description for Genmab located in Fresno, CA, as well as other career opportunities that the company...
solid tumorthe museregionalbusinessdirector